Our top pick for
Building a portfolio
Nurix Therapeutics, Inc is a biotechnology business based in the US. Nurix Therapeutics shares (NRIX) are listed on the NASDAQ and all prices are listed in US Dollars. Nurix Therapeutics employs 122 staff and has a trailing 12-month revenue of around USD$13 million.
|Latest market close||USD$32.88|
|52-week range||USD$15.21 - USD$50.825|
|50-day moving average||USD$38.5626|
|200-day moving average||USD$29.5844|
|Wall St. target price||USD$40.4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.8243|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||-19.82%|
|1 month (2020-12-22)||-27.50%|
|3 months (2020-10-19)||23.89%|
|6 months (2020-07-18)||N/A|
|1 year (2020-01-18)||N/A|
|2 years (2019-01-18)||N/A|
|3 years (2018-01-18)||N/A|
|5 years (2016-01-18)||N/A|
|Revenue TTM||USD$13 million|
|Gross profit TTM||USD$-13,910,000|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.6 billion|
TTM: trailing 12 months
There are currently 863,379 Nurix Therapeutics shares held short by investors – that's known as Nurix Therapeutics's "short interest". This figure is 0.6% up from 858,482 last month.
There are a few different ways that this level of interest in shorting Nurix Therapeutics shares can be evaluated.
Nurix Therapeutics's "short interest ratio" (SIR) is the quantity of Nurix Therapeutics shares currently shorted divided by the average quantity of Nurix Therapeutics shares traded daily (recently around 122291.64305949). Nurix Therapeutics's SIR currently stands at 7.06. In other words for every 100,000 Nurix Therapeutics shares traded daily on the market, roughly 7060 shares are currently held short.
However Nurix Therapeutics's short interest can also be evaluated against the total number of Nurix Therapeutics shares, or, against the total number of tradable Nurix Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nurix Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Nurix Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0339% of the tradable shares (for every 100,000 tradable Nurix Therapeutics shares, roughly 34 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nurix Therapeutics.
Find out more about how you can short Nurix Therapeutics stock.
We're not expecting Nurix Therapeutics to pay a dividend over the next 12 months.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.